Combined-modality therapy for rectal cancer: Future prospects

Clinical Colorectal Cancer

Volumn 6, Issue 9, 2007, Pages 625-633

  Czito, Brian G ^a   Willett, Christopher G ^a   Bendell, Johanna C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Capecitabine; Chemotherapy; Epidermal growth factor receptor; Irinotecan; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO;

ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; MONOTHERAPY; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM SURGERY; REVIEW; SURVIVAL; TREATMENT RESPONSE;

EID: 35348879318     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.030     Document Type: Review

References (88)

1. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974; 34:1278-1292.
2. Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52:1317-1329.
3. Prolongation of the disease free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312:1465-1472.
4. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-715.
5. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92:388-396.
6. Heald RJ. The "holy plane" of rectal surgery. J R Soc Med 1988; 81:503-508.
7. Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133:894-899.
8. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638-646.
9. Sebag-Mantefiore D, Steele R, Quirke P, et al. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer: Preliminary results of the MRC CR07 randomized trial. J Clin Oncol 2006; 24(18 suppl):148s (Abstract #3511).
10. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740.
11. Buiko K, Nowacki M, Nasirowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 75:15-24.
12. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-1123.
13. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24:4620-4625.
14. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5:2948-2953.
15. Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) versus bolus 5-FU/LV as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. Proc Am Soc Clin Oncol 2004; 22(14 suppl):247s (Abstract #3509).
16. Krishnan S, Janjan N, Skibber J, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced cancer. Int J Radiat Oncol Biol Phys 2006; 66:762-771.
17. Kim J, Kim T, Kim J, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63:346-353.
18. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17:246-251.
19. Dupuis O, Vie B, Lledo G, et al. Capecitabine chemoradiation in the preoperative treatment of patients with rectal adenocarcinomas: a phase II Gercor trial. Proc Am Soc Clin Oncol 2004; 23:255 (Abstract #3538).
20. Wong S, Sadasiwan C, Erickson B, et al. A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer. Presented at: the American Society of Clinical Oncology Gastrointestinal Proceedings; San Francisco, CA; January 22-24, 2004. Abstract #281.
21. Raymond E, Buquet-Fagot C, Djelloul S. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8:876-885.
22. Goldberg R, Sargent D, Morton R, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
23. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouricil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
24. Wolmark N, Weiland H, Kuebler J, et al. A phase III trial comparing FULV and FULV + oxaliplatin in stage II or stage III of the colon: results of NSABP Protocol C-07. J Clin Oncol 2005; 23(16 suppl):1092s (Abstract #3500).
25. Hess S, Blackstock W. Oxaliplatin: in vitro and in-vivo evidence of its radiosensitizing activity - preclinical observation relevant to ongoing clinical trials. Proceedings ARCR 2000; 41:A335.
26. Gerard J, Shapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: Lyon R0-04 phase II trial. J Clin Oncol 2003; 21:1119-1124.
27. Ryan D, Niedzwiecki D, Hollis D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2007; 24:2557-2562.
28. Rodel C, Liersch T, Hermann R, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25:110-117.
29. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol 2006; 24(18 suppl):253 (Abstract #3528).
30. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-3104.
31. Machiels J, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005; 16:1898-1905.
32. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG). Br J Cancer 2005; 31:993-998.
33. Glynne-Jones R, Sebag-Montefiore D, Maughan T, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2005; 17:50-56.
34. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
35. Zhu A, Willett C. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol 2003; 13:454-468.
36. Mitchell E, Anne R, Goldstein S, et al. Chemoradiation with irinotecan, 5-fluorouracil as neoadjuvant therapy of locally advanced rectal cancer. Presented at: the American Society of Clinical Oncology Gastrointestinal Proceedings; January 22-24, 2004; San Francisco, CA. Abstract #244.
37. Mehta V, Cho C, Ford J, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, in weekly CPT-11, followed by surgery for ultrasound stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55:132-137.
38. Willeke F, Horisberge K, Kraus-Tiefenbacher U, et al, A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Capiri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007; 96:912-917.
39. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer. Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24:650-655.
40. Hofheinz R, von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23:1350-1357.
41. Navarro M, Dotr E, River F, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:201-205.
42. Voelter V, Zouhair A, Vuilleumier H, et al. CPT-11 and concomitant hyperfractionated accelerated radiotherapy induced efficient local control in rectal cancer patients: results from a phase II. Br J Cancer 2006; 95:710-716.
43. Glynne-Jones R, Falk S, Maughan T, et al. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin in pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group study. Br J Cancer 2007; 96:551-558.
44. Klautke G, Kuchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly Irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006; 95:950.
45. Saeki T, Salomon D, Johnson G, et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995; 25:240-249.
46. Raymond E, Faivre S, Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(suppl 1):15-30.
47. Nicholson R, Gee J, Harper M. EGFR and cancer prognosis. Eur J Cancer 2001; 37:S9-S15.
48. Khorana A, Ryan C, Eberly S, et al. EGFR expression and survival in stage II, III and IV colon cancer. Proc Am Soc Clin Oncol 2003; 22:317 (Abstract #1272).
49. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
50. Raben D, Phistery M, Helfrich B, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor enhances radiation-induced cytotoxicity in human pancreatic and cholangiocarcinoma cell lines in vitro. Presented at: the Gastrointestinal Cancer Research Conference; November 16-18, 2000; Orlando, FL.
51. Raben D, Helfrich B, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29:37-46.
52. Williams K, Telfer B, Stratford I, et al. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86:1157-1161.
53. Magne N, Fischel J, Dubreuil A, et al. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9:4735-4742.
54. Fisher G, Kuo T, Cho C, et al. A phase II study of gefitnib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22(14 suppl):248s (Abstract #3514).
55. Rothenberg M, LaFleur B, Levy D, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005; 23:9265-9274.
56. Zeuli M, Gelibetr A, Nardoni C, et al. A feasibility study of getifinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer. J Clin Oncol 2004; 22(14 suppl):306s (Abstract #3748).
57. Townsley C, Major P, Siu L, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94:1136-1143.
58. Meyerhardt J, Zhu A, Enzinger P, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:1892-1897.
59. Czito B, Willett C, Bendell J, et al. Increased toxicity with gefitinib, capecitabine and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24:656-662.
60. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
61. Amgen Discontinues Vectibix™ Treatment in PACCE Trial Evaluating Vectibix™ as Part of Triple Combination Regimen. Amgen press release. Available at: http://www.amgen.com/media_pr_detail.jsp?year=2007&releaseID= 977186. Accessed March 22, 2007.
62. Giralt J, Eraso A, Armengol M, et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:1460-1465.
63. Azria D, Bibeau F, Barbier N, et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on locoregional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005; 5:62.
64. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005; 74:101-108.
65. Zhang W, Park D, Lu B, et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005; 11:600-605.
66. Kim J, Kim J, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:195-200.
67. Li S, Kim J, Kim J, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 65:705-712.
68. Spindler K, Nielsen J, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006; 66:500-504.
69. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
70. Chung K, Minsky B, Schrag D, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 2006; 24(18 suppl):256 (Abstract #3560).
71. Hofheinz R, Horisberge K, Woernle C, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:1384-1390.
72. Machiels J, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18:738-744.
73. Rodel C, Hipp M, Liersch T, et al. Cetuximab, capecitabine, oxaliplatin and radiation therapy as preoperative treatment in rectal cancer. Presented at: the 48th Annual Meeting of ASTRO; November 3-5, 2006; Philadelphia, PA.
74. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34:2041-2045.
75. Nanashima A, Ito M, Sekine I, et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 1998; 43:2634-2640.
76. Chin K, Greenman J, Gardiner E, et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000; 83:1425-1431.
77. Cascinus S, Garziano F, Catalano V, et al. Vascular endothelial growth factor (VEGF), p53, and BAX expression in node positive rectal cancer. Proc Am Soc Clin Oncol 2001; 20:26 (Abstract #595).
78. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
79. Giantonio B, Levy D, O'Dwyer P, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17:1399-1403.
80. Lee C, Heijin M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-5570.
81. Kozin S, Boucher Y, Hicklin D, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61:39-44.
82. Tong R, Boucher Y, Kozin S, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockage induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:373-376.
83. Winkler F, Kozin S, Tong R, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553-563.
84. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989.
85. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
86. Willett C, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
87. Willett C, Boucher Y, Duda D, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23:8136-8139.
88. Czito B, Bendell J, Willett C, et al. Bevacizumab, oxaliplatin and capecitabine with radiation therapy and rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68:472-478.